Status:
COMPLETED
GLORIA-AF Registry Program (Phase I)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
This study constitutes Phase I of the Registry Program. The main objective of this study is to characterize the newly diagnosed non-valvular AF patient population at risk for stroke and the selection ...
Detailed Description
Study Design: cross-sectional
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 1\) Patients newly diagnosed with non-valvular atrial fibrillation at risk for stroke.
- Exclusion criteria:
- Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention;
- Patients who have received more than 60 days of oral anticoagulant treatment (vitamin K antagonist) (VKA) in their lifetime;
- Atrial fibrillation (AF) with a generally reversible cause;
- Patients with a medical condition other than atrial fibrillation for which chronic use of an oral anticoagulant (VKAs) is indicated
Exclusion
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
1096 Patients enrolled
Trial Details
Trial ID
NCT01428765
Start Date
May 1 2011
End Date
January 1 2013
Last Update
March 5 2014
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
1160.114.08017 Boehringer Ingelheim Investigational Site
Beijing, China
2
1160.114.08018 Boehringer Ingelheim Investigational Site
Beijing, China
3
1160.114.08019 Boehringer Ingelheim Investigational Site
Beijing, China
4
1160.114.08020 Boehringer Ingelheim Investigational Site
Beijing, China